AJP - Endocrinology and Metabolism, Vol 256, Issue 5 E651-E661, Copyright © 1989 by American Physiological Society

ARTICLES

Insulin, glucagon, and catecholamines in prevention of hypoglycemia during fasting

P. J. Boyle, S. D. Shah and P. E. Cryer
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.

To dissect the mechanisms of the prevention of hypoglycemia during fasting, eight normal humans were studied after overnight and 3-day fasts. Prolonged fasting resulted in the expected decrements in base-line glucose production and plasma glucose, insulin, and C-peptide and increments in plasma glucagon, epinephrine, norepinephrine, growth hormone, and cortisol. After the overnight and 3-day fasts, insulin restoration (0.2 mU.kg-1.min-1) alone resulted in transient decrements in glucose production and only 15 and 19% decrements in plasma glucose, respectively. Selective glucagon deficiency (somatostatin infusion with insulin and growth hormone replacement) resulted in transient decrements in glucose production and additional 24 and 29% decrements in plasma glucose, respectively. Notably, plasma glucose plateaued under both fasting conditions in both instances. Combined alpha- and beta-adrenergic blockade (phentolamine and propranolol infusions) alone had no effect on glycemia under either fasting condition. However, progressive hypoglycemia developed during adrenergic blockade coupled with glucagon deficiency after the overnight fast (85 +/- 2 to 48 +/- 4 mg/dl, P less than 0.001) and after the 3-day fast (65 +/- 2 to 33 +/- 1 mg/dl, P less than 0.001). These were the result of both decrements in glucose production and increments in glucose clearance. Thus we conclude that during fasting 1) the prevention of hypoglycemia is not due solely to decreased insulin secretion. 2) Glucagon plays a primary counterregulatory role. Sympathochromaffin catecholamines are not normally critical but compensate and become critical when glucagon is deficient. Adrenomedullary epinephrine is probably the relevant catecholamine. 3) Other hormones, neurotransmitters, or substrate effects may, or may not, be involved; if they are, they appear to stand low in the hierarchy of glucoregulatory factors.

This article has been cited by other articles:

				M. A. Fowler, C. D. Champagne, D. S. Houser, and D. E. Crocker Hormonal regulation of glucose clearance in lactating northern elephant seals (Mirounga angustirostris) J. Exp. Biol., September 15, 2008; 211(18): 2943 - 2949. [Abstract] [Full Text] [PDF]

				D. S. Houser, C. D. Champagne, and D. E. Crocker Lipolysis and glycerol gluconeogenesis in simultaneously fasting and lactating northern elephant seals Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2007; 293(6): R2376 - R2381. [Abstract] [Full Text] [PDF]

				B. Raju and P. E. Cryer Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon? Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E181 - E186. [Abstract] [Full Text] [PDF]

				K. Hojlund, M. Wildner-Christensen, O. Eshoj, C. Skjarbak, J. J. Holst, O. Koldkjar, D. Moller Jensen, and H. Beck-Nielsen Reference intervals for glucose, {beta}-cell polypeptides, and counterregulatory factors during prolonged fasting Am J Physiol Endocrinol Metab, January 1, 2001; 280(1): E50 - E58. [Abstract] [Full Text] [PDF]

				F. Fery, L. Plat, P. van de Borne, E. Cogan, and J. Mockel Impaired Counterregulation of Glucose in a Patient with Hypothalamic Sarcoidosis N. Engl. J. Med., March 18, 1999; 340(11): 852 - 856. [Full Text] [PDF]

				F.J. Service Hypoglycemic Disorders N. Engl. J. Med., April 27, 1995; 332(17): 1144 - 1152. [Full Text] [PDF]